INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,633,633 | -17.3% | 146,547 | +0.6% | 0.01% | -9.1% |
| Q2 2023 | $9,227,877 | +25.0% | 145,734 | +6.9% | 0.01% | +10.0% |
| Q1 2023 | $7,379,942 | +2.3% | 136,287 | -0.0% | 0.01% | 0.0% |
| Q4 2022 | $7,213,525 | +14.8% | 136,310 | +0.9% | 0.01% | +11.1% |
| Q3 2022 | $6,286,296 | -9.7% | 135,102 | +10.7% | 0.01% | -50.0% |
| Q2 2022 | $6,965,000 | +7.6% | 122,010 | +15.3% | 0.02% | +38.5% |
| Q1 2022 | $6,472,000 | +344.5% | 105,782 | +280.3% | 0.01% | +333.3% |
| Q4 2021 | $1,456,000 | +40.4% | 27,819 | +0.0% | 0.00% | +50.0% |
| Q3 2021 | $1,037,000 | -8.6% | 27,806 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,135,000 | +14.0% | 27,806 | -5.3% | 0.00% | 0.0% |
| Q1 2021 | $996,000 | +10.2% | 29,350 | +3.2% | 0.00% | 0.0% |
| Q4 2020 | $904,000 | +61.1% | 28,432 | +30.1% | 0.00% | +100.0% |
| Q3 2020 | $561,000 | +13.3% | 21,857 | +13.3% | 0.00% | 0.0% |
| Q2 2020 | $495,000 | +24.7% | 19,296 | -25.4% | 0.00% | 0.0% |
| Q1 2020 | $397,000 | -47.8% | 25,860 | +16.8% | 0.00% | -50.0% |
| Q4 2019 | $760,000 | +420.5% | 22,137 | +13.7% | 0.00% | – |
| Q3 2019 | $146,000 | -42.3% | 19,478 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $253,000 | +6.8% | 19,478 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $237,000 | +6.8% | 19,478 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $222,000 | -44.5% | 19,478 | +5.6% | 0.00% | 0.0% |
| Q3 2018 | $400,000 | +22.7% | 18,447 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $326,000 | -14.2% | 18,447 | +2.1% | 0.00% | 0.0% |
| Q1 2018 | $380,000 | +45.0% | 18,066 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $262,000 | -1.9% | 18,066 | +6.8% | 0.00% | 0.0% |
| Q3 2017 | $267,000 | +27.1% | 16,911 | 0.0% | 0.00% | – |
| Q2 2017 | $210,000 | -11.4% | 16,911 | +16.0% | 0.00% | -100.0% |
| Q1 2017 | $237,000 | +7.7% | 14,573 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $220,000 | -0.9% | 14,573 | 0.0% | 0.00% | – |
| Q3 2016 | $222,000 | -60.8% | 14,573 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $566,000 | +108.9% | 14,573 | +49.5% | 0.00% | 0.0% |
| Q1 2016 | $271,000 | -48.3% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $524,000 | +34.4% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $390,000 | -1.0% | 9,749 | -20.9% | 0.00% | 0.0% |
| Q2 2015 | $394,000 | +34.0% | 12,331 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $294,000 | +34.9% | 12,331 | 0.0% | 0.00% | – |
| Q4 2014 | $218,000 | +29.0% | 12,331 | 0.0% | 0.00% | – |
| Q3 2014 | $169,000 | -18.8% | 12,331 | 0.0% | 0.00% | – |
| Q2 2014 | $208,000 | – | 12,331 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |